ADMA Biologics receives FDA approval to expand ASCENIV label to pediatric patients 2 years+

ADMA BIOLOGICS, INC.

FDA approved label expansion for ASCENIV to include pediatric primary humoral immunodeficiency patients aged 2 years and older.
Previously approved only for patients 12 years and older; approval fulfills post-marketing pediatric assessment commitment.
CEO Adam Grossman: expanded label allows addressing treatment needs of younger PI patients earlier in their treatment journey.
COO Kaitlin Kestenberg highlighted collaboration with PI community and families; approval reflects strong clinical execution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.